Back

Gender and racial differences in outcomes among patients with NVAF treated with oral anticoagulants: a real-world evaluation of Medicare beneficiaries

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Antithrombotic and anticoagulant therapy in special populations Anticoagulants ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Dong Cheng

(United States of America)

8 More presentations in this session

Presentation thumbnail
Direct oral anticoagulants exhibit lower risks of mortality and bleeding compared to vitamin-k antagonists in atrial fibrillation patients on chronic hemodialysis: a meta-analysis
Doctor H. Jain (Jodhpur, IN)
Abstract Slides Video
Presentation thumbnail
Medication adherence and antithrombotic therapy outcomes: insights from a post-hoc analysis of the AFIRE trial
Doctor N. Chiba (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Impact of differences in body mass index, body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe
Professor G. Boriani (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Haemorrhagic risk in elderly patients with atrial fibrillation that develop low platelet count during direct oral anticoagulant treatment: insights from the ATHERO-AF study.
Doctor D. Menichelli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Silent cerebral microvascular disease and longitudinal risk of cognitive decline in atrial fibrillation
Associate Professor Y. Kondo (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Antithrombotic and anticoagulant therapy in special populations

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Racial and ethnic disparities in the incidence of stroke and mortality in atrial fibrillation: a US nationwide study
thumbnail
Congress Presentation
Mitigating health disparities by improving access to catheter-based therapies for vulnerable patients with acute pulmonary embolism
thumbnail
Congress Presentation
Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources